ODDITY Tech delivered the cleanest evidence yet that its 2026 slump is bottoming. Third-quarter adjusted earnings of $0.37 per share beat the $0.30 consensus by 15.6% and cleared the $0.32 Earnings Whisper number. Revenue of $144.98 million topped the $141.25 million consensus by 2.6%. Revenue fell just 2.0% year over year, a sharp improvement from declines of roughly 25% in the second quarter and 26% in the first, and well ahead of management's own guide for a 5% decline. Adjusted EBITDA of $22 million beat the $18 million to $20 million outlook, and full-year guidance moved higher. The central tension is that the top-line inflection is real, but the profit picture underneath it is still deteriorating, and the problem that started the downturn remains unsolved.

The quality of the beat deserves scrutiny. Adjusted EPS fell only 5.1% year over year, but adjusted net income dropped to $18 million from $25 million. The gap reflects aggressive share repurchases: diluted shares fell to about 48 million from nearly 63 million a year ago, and the company bought back roughly $163 million of stock in the first nine months. On a GAAP basis, diluted EPS was $0.23 versus $0.28. Gross margin compressed to 67.4% from 71.6% a year earlier, extending a sequential slide from 69.7% in the first quarter and 68.7% in the second. Management tied the slide to mid-single-digit declines in average order value. Cash generation has also thinned sharply. Free cash flow was $10 million in the quarter but only about $2.5 million year to date, versus nearly $90 million in the same period last year. Inventory climbed to $158 million from $135 million at year-end, and cash and investments fell to $561 million from $776 million.

The call explained why the revenue line turned. Repeat orders, which make up more than 80% of revenue, stabilized year over year after falling about 20% in the second quarter. First-order revenue is still down in the high teens, but that compares with drops of roughly 40% and 50% in the prior two quarters. SpoiledChild remains the growth engine, on track to grow at least 35% and approach $350 million in 2026 revenue. METHODIQ is now expected to beat SpoiledChild's first-year revenue, an upgrade from earlier framing of roughly in line. IL MAKIAGE is the weak spot. Its ad-account dislocation with the company's largest advertising partner is still unresolved after three quarters, despite earlier hopes for second-half normalization. Management cited September customer acquisition costs as the best since 2025, then conceded October was worse. The CEO's language that the company is "hopeful" it is on a path to normalization is not a fix.

The guidance raise is also less than it appears. Full-year revenue guidance improved only to a decline of about 18.5% from 19%. Fourth-quarter guidance calls for revenue down 10% to 11% and adjusted EBITDA of just $4 million to $6 million, which leaves the implied fourth quarter essentially unchanged. Most of the raise is simply the third-quarter beat flowing through. Looking further out, the catalysts are substantive:

• METHODIQ's move into longevity and metabolic health, including prescription injectables such as NAD+ and sermorelin plus six peptide therapies.
• A fourth brand planned for 2027.
• What management called its most exciting product slate ever.
• New distribution channels, with Amazon not ruled out.

The risks are just as substantive. The peptide opportunity rests on a non-binding HHS enforcement discretion policy, will draw many telehealth competitors at once, and carries higher upfront acquisition costs. Management also flagged that returning to growth in 2027 will require heavier acquisition spending, which points to further margin pressure.

Investor sentiment shifted meaningfully into the report, rising from a negative -0.38 after the September release to a slightly positive 0.08. The stock tells a similar but more nuanced story. Shares entered the report at $19.51, up 11.5% from the opening price after the prior release and 14% above the 200-day moving average of $17.10. They also sat 17.8% below the October 20 high of $23.73, having given back much of an early-autumn rally from the $14.57 low set on the last report day. Price and AVWAP trends are positive, but the retreat from the highs suggests the market was already discounting the IL MAKIAGE uncertainty.

The bottom line is that ODDITY's quarter preserved a credible recovery story: revenue nearly stopped shrinking, repeat demand stabilized, and SpoiledChild and METHODIQ are carrying the portfolio. Bears still have legitimate ammunition. Gross margins keep falling, buybacks are flattering EPS, cash flow has dried up, the fourth-quarter outlook did not improve, and the IL MAKIAGE acquisition problem remains unresolved. Durable improvement now depends on fixing that dislocation before 2027's heavier investment cycle squeezes margins further.